Development of a novel plastic nanomedicine for anti-angiogenic cancer therapy.
| Project/Area Number |
26888014
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Polymer chemistry
|
|---|
| Research Institution | University of Shizuoka |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-08-29 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | がん / ナノ粒子 / VEGF / 血管新生 / 高分子 / 糖 |
|---|
| Outline of Final Research Achievements |
Synthetic polymer hydrogel nanoparticles (NPs) capable of capturing and/or releasing target biomacromolecules are of interest as alternative bioaffinity ligands. Recently, poly-N-isopropylacrylamide (pNIPAm) based NPs have been prepared with the capacity to bind and neutralize the hemolytic toxin melittin. These NPs were found to neutralize the toxicity of melittin in vivo. Here, we focused on developing a synthetic NP for anticancer therapy by capturing and inhibiting the vascular endothelial growth factor (VEGF). NP affinity for VEGF165 was found to be very sensitive to the relative amounts of functional monomers. An optimized NP containing sulfated N-acetylglucosamine monomers strongly inhibited VEGF165-dependent VEGFR-2 phosphorylation and cell growth in vitro.
|
Report
(2 results)
Research Products
(5 results)
